Podcasts about duke nus medical school

There has been growing concern over bird flu globally in recent weeks, with a number of countries reporting cases in humans, and the first fatality from avian influenza in the US. Bird flu is a disease caused by a virus that infects birds, and sometimes other animals. Bird migration has resulted in outbreaks of the avian flu in domestic and wild birds. The H5N1 virus is the major strain circulating among wild birds worldwide, and emerged in China in the late 1990s. Will it become the next global pandemic? On this episode of Breakfast Special, Professor Gavin Smith, Director of the Programme in Emerging Infectious Diseases at Duke-NUS Medical School shares his expert insights. Presented by: Audrey SiekProduced & Edited by: Yeo Kai Ting (ykaiting@sph.com.sg)Assistant Producer: Muhammad Nazirul AsrarPhoto credits: CDC/NIAID/APSee omnystudio.com/listener for privacy information.

By 2030, about one in four citizens in Singapore will be aged 65 and above. The rising burden of caregiving is coming into focus, with the little red dot's population rapidly ageing. Just recently, Singapore's labour movement committed a total of $5.4 million over the next three years to support lower-income union members with caregiving responsibilities at home. The role of informal caregivers too, is set to become even more critical. According to a recent study by the Centre for Ageing Research and Education, despite the significant time commitment, the monetary value of informal caregiving is often overlooked in eldercare cost estimates, with most studies focusing only on direct healthcare costs. On this episode of Morning Shot, Associate Professor Rahul Malhotra, Deputy Director of the Centre for Ageing Research and Education at Duke-NUS Medical School shares his insights. Presented by: Audrey Siek & Emaad AkhtarProduced & Edited by: Yeo Kai Ting (ykaiting@sph.com.sg)Photo credits: Gin Tay / STSee omnystudio.com/listener for privacy information.

What will we do when Disease X strikes? Scientists around the world are racing against the clock to prevent another global pandemic from happening. From cutting edge research labs to the sewers of Singapore, Claressa Monteiro goes virus hunting with the world's leading experts on emerging infectious diseases. Professor Wang Linfa from Duke-NUS Medical School is working on a universal coronavirus vaccine. Dr. Judith Wong and her team are monitoring sewer waters for the first signs of an outbreak. And Dr. Mary Rodgers is solving mystery illnesses popping up around the world. Synopsis: A monthly podcast series from The Business Times on current affairs, societal issues and government policies explored through the lens of how it impacts us in Singapore and in the region. Highlights of the conversation: 03:49 Why viruses love bats 08:07 Solving the case of a mystery patient 13:55 Testing sewer waters in Singapore 21:05 The 100 days mission --- Now, we want to hear from you! Send us your questions, thoughts, story ideas, and feedback to btpodcasts@sph.com.sg. We'll look into it for future episodes. --- Hosted by: Claressa Monteiro (claremb@sph.com.sg) With Professor Wang Linfa, director of the Emerging Infectious Diseases Programme, Duke-NUS Medical School; Dr. Mary Rodgers, associate research fellow, Abbott; and Dr. Judith Wong, director of the Microbiology and Molecular Epidemiology Division, National Environment Agency. Edited by: Claressa Monteiro & Emily Liu Produced by: Emily Liu & Claressa Monteiro Engineered by: Joann Chai Pei Chieh A podcast by BT Podcasts, The Business Times, SPH Media --- Follow BT Lens On:  Channel: bt.sg/btlenson Amazon: bt.sg/lensam Apple Podcasts: bt.sg/lensap Spotify: bt.sg/lenssp Website: bt.sg/lenson Youtube Music: bt.sg/lensyt  Do note: This podcast is meant to provide general information only. SPH Media accepts no liability for loss arising from any reliance on the podcast or use of third party's products and services. Please consult professional advisers for independent advice.  --- Discover more BT podcast series: BT Money Hacks: bt.sg/btmoneyhacks BT Mark To Market: bt.sg/btmark2mkt PropertyBT: bt.sg/btpropertybt WealthBT: bt.sg/btwealthbt BT Market Focus: bt.sg/btmktfocus BT Podcasts: bt.sg/pcOM BT Branded Podcasts at: bt.sg/brpodSee omnystudio.com/listener for privacy information.

Patients have reported waiting for days to get a bed at a public hospital. Health experts say the biggest reason is that there are issues transiting to proper care after discharge. Otelli Edwards speaks to public health specialist Dr Jeremy Lim, Duke-NUS Medical School's Dr David Matchar and Jeremy Lee, assistant chief operating officer at the National University Hospital.  See omnystudio.com/listener for privacy information.

Dengue has been significantly on the rise this year across Southeast Asia and in Singapore, the NEA has warned of a new surge in dengue cases in recent months. WHO's Strategic Advisory Group of Experts on Immunization (SAGE) has released recommendations for the use of dengue vaccine QDENGA. But how effective are vaccines when it comes to fighting dengue?  Ooi Eng Eong, Professor in Emerging Infectious Diseases, DUKE-NUS Medical School shares his views. See omnystudio.com/listener for privacy information.

In this enlightening episode of Inside GRAPPA, we delve deep into the intricate world of peripheral arthritis in psoriatic disease. Today's host, Dr. Sebastian Herrera, is joined by the esteemed Dr. Katy Leung, and Professor Oliver Fitzgerald to discuss the significance, manifestation, and management of peripheral arthritis in patients with psoriatic disease.Dr. Herrera is a rheumatologist at Clínica Las Américas Auna and ARTMEDICA in Medellín, Colombia and also an Associate Professor of Rheumatology at Universidad CES and a member of Young GRAPPA. Dr. Leung is an Associate Professor at Singapore General Hospital and Duke-NUS Medical School in Singapore. Dr. Leung has interest in clinical and translational research in PsA, is the co-chair of the GRAPPA-OMERACT Outcome Measure Working group, and is also a member of the GRAPPA Education Committee. Dr. Fitzgerald is based at University College Dublin and has a major interest in clinical and translational research in PsA. More recent studies have explored genetic factors and biomarker development. Dr. Fitzgerald has been involved for many years with GRAPPA and took up the office of co-President in July 2021. He has been advocating for grant application opportunities addressing critical unmet needs in PsA for some time and this has culminated in the award of the first, significant, joint EU/industry funded Innovative Medicines Initiative (IMI) grant in PsA, the HIPPOCRATES consortium.

In this episode:We dive deep into some groundbreaking new research from the Duke-NUS Medical School and the National University of Singapore that could potentially revolutionize how we understand the development and aging of the brain.We introduce you to a 'superhero' protein called Mfsd2a and its role as a transporter of a lipid containing an omega-3 fatty acid, known as lysophosphatidylcholine (LPC), which is vital for the process of myelination.We explore the implications of this research for those living with MS and other neurological disorders. The potential therapeutic benefits of LPC omega-3 lipids could help maintain or even improve myelination in the aging brain.We discuss the future of this research as the team now aims to conduct further preclinical studies to see if dietary LPC omega-3 can help re-myelinate damaged axons in the brain.Referenced Article: https://www.sciencedaily.com/releases/2023/05/230505101659.htmTune in again for more exciting updates from the world of MS research. Remember, you're not alone on this journey, and together, we can make a difference.Enjoyed the show? Please leave us a review and share it with someone who might benefit from it.Stay connected and let us know your thoughts via our social media channels. Until next time, keep the hope alive!https://www.sciencedaily.com/releases/2023/05/230505101659.htmThe Just MS (Multiple Sclerosis) Show, w host Justin Loizos, is a podcast that connects, educates and tries to uplift others living with multiple sclerosis. It provides real-life stories, interviews, and information about DMTs (disease modification therapies) and updates on research developments.www.justmultiplesclerosis.com

With Bibhas Chakraborty, Duke-NUS Medical School, and Nick Seewald, Johns Hopkins Bloomberg School of Public Health, we discuss current limitations for public health of the classical way of conducting RCTs, give examples of these limitations, and explain why sequential, multiple-assignment randomized trials (SMARTs) and microrandomized trials (MRTs)help overcoming these limitations.

In this special edition on China's new face in the fight against COVID-19, Liu Xin had an exclusive dissection of the details with Dr. Shao Yiming, former Chief Expert on AIDS at the Chinese Center for Disease Control and Management, and a current member of the Vaccine Task Force of the Central Government's COVID Control Mechanism; Dr. Kate Tulenko, CEO of the health workforce company Corvus Health, and Former Vice President of Health Systems Innovation; and from Singapore Prof. Wang Linfa, Emerging Infectious Disease at the Duke-NUS Medical School.

From 2020 to 2022, the number of people caught vaping has more than tripled. The use of e-cigarettes has entrenched itself, not just among the young who are attracted by the lower costs and different flavours, but also by adults who are convinced that this is less harmful compared to cigarettes. What does the research say and why aren't current enforcement measures working? Steven Chia speaks to Associate Professor Bibhas Chakraborty from Duke-NUS Medical School, Sean Ang, a smoking cessation specialist and “Sarah”, who vapes. See omnystudio.com/listener for privacy information.

A new virus, which can be transmitted to humans from animals, has infected 35 people in Shandong and Henan provinces. That's according to a study by scientists from China, Singapore and Australia published in the New England Journal of Medicine. So far, there has been no evidence of human-to-human transmission. The Henipavirus (also called Langya henipavirus or LayV) was first detected in late 2018 but was formally identified by scientists only last week. In The Straits Times' The Big Story, Multimedia journalist Hairianto Dirman spoke with Dr Zhu Feng, a research fellow from the Emerging Infectious Diseases Programme at Duke-NUS Medical School about the study. See omnystudio.com/listener for privacy information.

Videos: The healthcare system is a giant SCAM (that you pay for) – Sorelle Amore Finance Failure after failure: Private hospitals' appalling treatment of pregnant mum | 60 Minutes Australia   HEALTH NEWS B vitamins can potentially be used to treat advanced non-alcoholic fatty liver disease Decreased acetyl-L-carnitine levels associated with depression Skip the texts: Face-to-face meetings make college students happier Eating more plant protein associated with lower risk of death Heat therapy boosts mitochondrial function in muscles Your soap and toothpaste could be messing with your microbiome   B vitamins can potentially be used to treat advanced non-alcoholic fatty liver disease Duke University Medical School, August 6, 2022 Scientists at Duke-NUS Medical School have uncovered a mechanism that leads to an advanced form of fatty liver disease—and it turns out that vitamin B12 and folic acid supplements could reverse this process. These findings could help people with non-alcoholic fatty liver disease, an umbrella term for a range of liver conditions affecting people who drink little to no alcohol, which affects 25% of all adults globally, and four in 10 adults in Singapore.  Non-alcoholic fatty liver disease involves fat build-up in the liver and is a leading cause of liver transplants worldwide. When the condition progresses to inflammation and scar tissue formation, it is known as non-alcoholic steatohepatitis (NASH).  Dr. Tripathi, study co-author Dr. Brijesh Singh and their colleagues in Singapore, India, China and the US confirmed the association of homocysteine with NASH progression in preclinical models and humans. They also found that  when homocysteine attached to a protein called syntaxin 17, it blocked the protein from performing its role of transporting and digesting fat (known as autophagy, an essential cellular process by which cells remove malformed proteins or damaged organelles) in fatty acid metabolism, mitochondrial turnover, and inflammation prevention. This induced the development and progression of fatty liver disease to NASH.  Importantly, the researchers found that supplementing the diet in the preclinical models with vitamin B12 and folic acid increased the levels of syntaxin 17 in the liver and restored its role in autophagy. It also slowed NASH progression and reversed liver inflammation and fibrosis.    Decreased acetyl-L-carnitine levels associated with depression Stanford University, July 30 2022.  An article that in the Proceedings of the National Academy of Sciences reported a link between low levels of acetyl-L-carnitine and a greater risk of depression. Acting on the findings of animal research conducted by lead author Carla Nasca, PhD, the researchers recruited men and women between the ages of 20 and 70 years who had been admitted to Weill Cornell Medicine or Mount Sinai School of Medicine for treatment of acute depression. Clinical assessments were conducted upon enrollment and blood samples were analyzed for levels of acetyl-L-carnitine. In comparison with levels measured in blood samples provided by 45 demographically matched healthy men and women, acetyl-L-carnitine blood levels in depressed subjects were substantially lower. Acetyl-L-carnitine levels were lowest among depressed patients who had severe symptoms, a history of treatment resistance, or early onset disease. Having a history of childhood abuse was also associated with low acetyl-L-carnitine levels. “We've identified an important new biomarker of major depression disorder,” Dr Rasgon stated. What's the appropriate dose, frequency, duration? We need to answer many questions before proceeding with recommendations, yet.    Skip the texts: Face-to-face meetings make college students happier University of Hamburg (Germany), August 5, 2022 In a world where everyone spends more and more time with eyes fixed on their phones, new research suggests young people feel happier after socializing with friends in person rather than virtually The conclusion is an outgrowth of nearly four years spent analyzing how social habits of more than 3,000 college students affected their state of mind. “The findings of this study suggest that talking to people face to face makes us feel better than texting back and forth, for example,” said James Maddux, senior scholar at the Center for the Advancement of Well-Being in Fairfax, Va., who reviewed the results. Led by Lara Kroencke, of the University of Hamburg in Germany, the researchers noted that other studies have consistently shown that people tend to feel better after socializing with others.To better explore that question, Kroencke's team conducted three studies between 2017 and 2020 with students from the University of Texas at Austin. Researchers chose that age group because of the “intense” socializing that tends to take place during that phase of life. Participants between 18 and 24 years old; 37% were white, 23% were Asian, 23% were Hispanic, nearly 5% were Black, and the rest identified as multiracial. The result: Students tended to feel best after interacting with others in person or through a mix of in person and virtual, versus entirely by computer or phone. Interacting only virtually was, however, better for well-being than no interaction at all, the team stressed. They also found that socializing with close friends brought about a greater overall sense of well-being than engaging with either family or someone a person didn't know so well. And those who tended towards high levels of neuroticism were likely to benefit the most from in-person interactions.   Eating more plant protein associated with lower risk of death  Massachusetts General Hospital & Harvard Medical School, July 31, 2022  Eating more protein from plant sources was associated with a lower risk of death and eating more protein from animals was associated with a higher risk of death, especially among adults with at least one unhealthy behavior such as smoking, drinking and being overweight or sedentary, according to an article published online by JAMA Internal Medicine. Mingyang Song, M.D., Sc.D., of Massachusetts General Hospital and Harvard Medical School, Boston, and coauthors used data from two large U.S. studies that had repeated measures of diet through food questionnaires and up to 32 years of follow-up.  Among 131,342 study participants, 85,013 (64.7 percent) were women and the average age of participants was 49. Median protein intake, measured as a percentage of calories, was 14 percent for animal protein and 4 percent for plant protein. The authors report: After adjusting for major lifestyle and dietary risk factors, every 10 percent increment of animal protein from total calories was associated with a 2 percent higher risk of death from all causes and an 8 percent increased risk of death from cardiovascular disease death. In contrast, eating more plant protein was associated with a 10 percent lower risk of death from all causes for every 3 percent increment of total calories and a 12 percent lower risk of cardiovascular death. Increased mortality associated with eating more animal protein was more pronounced among study participants who were obese and those who drank alcohol heavily. The association between eating more plant protein and lower mortality was stronger among study participants who smoked, drank at least 14 grams of alcohol a day, were overweight or obese, were physically inactive or were younger than 65 or older than 80. Substituting 3 percent of calories from animal protein with plant protein was associated with a lower risk of death from all causes: 34 percent for replacing processed red meat, 12 percent for replacing unprocessed red meat and 19 percent for replacing eggs.   Heat therapy boosts mitochondrial function in muscles Brigham Young University, August 2, 2022 A new study finds that long-term heat therapy may increase mitochondrial function in the muscles. The discovery could lead to new treatments for people with chronic illness or disease. The study–the first of its kind in humans–is published in the Journal of Applied Physiology. Mitochondria, the “energy centers” of the cells, are essential for maintaining good health.  Exercise has been shown to create new mitochondria and improve function of existing mitochondria. However, some people with chronic illnesses are not able to exercise long enough–previous research suggests close to two hours daily–to reap the benefits. Rodent studies have suggested that heat exposure may also induce the production of more mitochondria. Researchers from Brigham Young University in Utah studied 20 adult volunteers who had not participated in regular exercise in the three months prior to the study. The research team applied two hours of shortwave diathermy–a type of heat therapy generated by electrical pulses–to the thigh muscles of one leg of each person every day. The researchers based the six-day trial of heat on the minimum amount of exercise needed to measure changes in muscle, or about two hours each day. They designed the treatment to mimic the effects of muscle heating that occurs during exercise. The therapy sessions increased the temperature of the heated leg by approximately 7 degrees F. Each participant's other leg served as a control, receiving no heat therapy or temperature change. The researchers looked at mitochondria content in the muscles on the first day of therapy and 24 hours after the last treatment. Mitochondrial function increased by an average of 28 percent in the heated legs after the heat treatment. The concentration of several mitochondrial proteins also increased in the heated legs, which suggests that “in addition to improving function, [repeated exposure to heat] increased mitochondrial content in human skeletal muscle,” the research team wrote.     Your soap and toothpaste could be messing with your microbiome University of Chicago, August 2, 2022 Antimicrobial chemicals found in common household products could be wreaking havoc with people's guts, according to a research paper out this week in the journal Science. Triclosan is an antibacterial compound used in soaps, detergent and toothpaste, as well as toys and plastics. It was originally only used in hospitals, but it found its way into homes as Americans became more germ-phobic. (However, recent studies have found it no more effective at killing bacteria than plain soap. ) Now, there are growing concerns about the possible negative effects of the chemical on human health and the environment. According to the US Food and Drug Administration (FDA), animal studies have shown that the chemical can act as a hormone disruptor. A study found traces of triclosan in the urine of 75% of the participants – some as young as six. The chemical has also been found in more than half of freshwater streams in the US. The latest research paper, written by academics from the University of Chicago, focused on the lesser-known effects of triclosan exposure on the bacteria in people's guts. Disturbing the human microbiome has been “linked to a wide array of diseases and metabolic disorders, including obesity, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and behavioral and metabolic disorders,” wrote the paper's authors, Alyson L Yee and Jack A Gilbert. To test the chemical's effect in humans, researchers from Stanford and Cornell universities gave seven volunteers triclosan-containing products, such as toothpaste and liquid soap, to use for four months. After that period, the same volunteers were switched to products without triclosan. The volunteers were compared with a second group who first used the non-triclosan products, then changed to those containing triclosan. The results showed that more triclosan was found in the urine of all the participants during the periods when they were using triclosan-containing products. Yee and Gilbert also suggested that exposure to triclosan could be even more detrimental to the health of developing fetuses and newborns than to adults. A 2014 New York University study found that gut disruptions in early infancy could have lasting negative effects on immune and brain development.

We get some answers from Dr Khoo Yoong Khean, scientific officer at the Centre for Outbreak Preparedness in Duke-NUS Medical School following the World Health Organization declaration of monkeypox as a public health emergency of international concern.Image credit: Poetra.RH / Shutterstock.com

TRC Editor, Dr. Lori Dickerson, PharmD, FCCP talks with two distinguished experts about new heart failure guidelines. Carolyn Lam, MBBS, PhD, FRCP, Professor at Duke-NUS Medical School and a Senior Consultant at the National Heart Centre SingaporeSteven E. Nissen, MD, MACC, the Chief Academic Officer at the Heart and Vascular Institute and the Lewis and Patricia Dickey Chair in Cardiovascular Medicine Professor of Medicine at the Cleveland Clinic Lerner School of Medicine at Case Western Reserve UniversityListen in as they discuss new guidelines for managing heart failure with reduced ejection fraction (HFrEF)...and put this new guidance in perspective.You'll also hear practical advice from panelists on TRC's Editorial Advisory Board:Andrea Darby Stewart, MD, Associate Director, Family Medicine Residency at Honor HealthAnthony A. Donato, Jr., MD, MHPE, Associate Program Director, Internal Medicine from the Reading Health System, and Professor of Medicine at the Sidney Kimmel Medical College at Thomas Jefferson UniversityCraig D. Williams, PharmD, FNLA, BCPS, Clinical Professor, Department of Pharmacy Practice at the Oregon Health and Science UniversityFor the purposes of disclosure, Dr. Carolyn Lam reports relevant financial relationships with Bayer, Roche Diagnostics (grants/research support); Abbott, Actelion, Alleviant Medical, Allysta Pharmaceuticals, Amgen, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc., EchoNous Inc, Impulse Dynamics, Ionis Pharmaceuticals, Janssen, Merck, Novartis, Novo Nordisk, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics, Us2.ai (advisory board/steering committee/executive committee); Us2.ai (stock shareholder); Us2.ai (non-executive director).Dr. Steven Nissen reports a relevant financial relationship with AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Esperion, Medtronic, Novartis, Pfizer, Silence Therapeutics (grants/research support).The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.Pharmacist's Letter offers CE credit for this podcast. Log in to your Pharmacist's Letter account and look for the title of this podcast in the list of available CE courses.If you're not yet a Pharmacist's Letter subscriber, find out more about our product offerings at trchealthcare.com. Follow or subscribe, rate, and review this show in your favorite podcast app. You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com. 

In this episode, we welcome Ani Sharma, Director of Communications & Strategic Relations at Duke-NUS Medical School in Singapore. Reflecting on his 22 years of experience in advancement, Ani shares how working across India, the Middle East, and Singapore has developed his cultural understanding and how he uses this knowledge in his current role. Listen in to hear his insights on measuring impact and outcomes in communications and why communication leaders should have a seat at the table.

Singapore has already placed orders for paediatric vaccines, trials are planned for at KK Hospital and the multi-ministry task force will announce its decision soon. Yet, among some parents there seems to be a niggling fear despite clinical trials showing good outcomes for children aged five to 11. Lin Suling sits down with Dr Lim Yang Chern, Paediatrician at Thomson Paediatric Centre, Ashley St John, Associate Professor at Duke-NUS Medical School, and Cherie Tseng, Chief Operations Officer at a local fintech company and mother of three kids aged four to 11 to find out what the data shows about side effects, if dosing amounts are safe and why parents don't hesitate in getting themselves vaccinated but seem to wring hands when it comes to younger children. See omnystudio.com/listener for privacy information.

“We have to learn to live with COVID-19” is a phrase we’ve been hearing all too often these days. Health Minister Khairy Jamaluddin has reiterated that we need to reopen safely and to start treating COVID-19 as endemic. Our neighbour down south, Singapore, has stayed the course of reopening the economy, despite rising COVID-19 cases. Over in New Zealand, Prime Minister Jacinda Ardern has finally dropped their zero-COVID strategy as the Delta variant persists. But are we truly ready to treat COVID-19 as endemic? Well, ready or not, the virus is likely here to stay. Prof Dr Ooi Eng Eong from the Emerging Infectious Diseases Programme at the Duke-NUS Medical School joins consultant urologist Dr George Lee to discuss how we can prepare ourselves for this new reality. Editor's note - Prof Ooi has further clarified on the antibody & T-cell response generated by vaccines, in particular the lack of T-cell response after receiving an inactivated virus vaccine: The lack of killer T-cells may not necessarily affect the durability of immunity. Instead, without such T-cells, immunity would be reliant only on the antibodies produced from vaccination. If these are not at levels needed to protect against infection, there is no killer T-cell response to quickly remove the infected cells. In other words, there is no backup protection. For more on the role of boosters/third doses of the COVID-19 vaccine, listen to this podcast with infectious disease physician Dr Yasmin Gani from Hospital Sungai Buloh.Image credit: Pexels

In The Straits Times' The Big Story, assistant video editor Olivia Quay spoke to Professor Ooi Eng Eong, from the infectious diseases programme at Duke-NUS Medical School on why he believes that the closure of premises with clusters is "not necessary". He also tells The Big Story that Singapore needs to let go of its past success with Covid-19 in order to move forward to living with an endemic disease. See omnystudio.com/listener for privacy information.

Health Check Ep 68 (Pt 2): Vaccine expert on combating new Covid variants 20:02 mins Synopsis: Every first and third Wednesday of the month, The Straits Times helps you make sense of health matters that affect you. In this episode, ST senior health correspondent Joyce Teo speaks with Prof Ooi Eng Eong from the Duke-NUS Medical School's Programme in Emerging Infectious Diseases about the current Covid-19 situation and how vaccination will lead us out of this pandemic. In the second part of their conversation, Prof Ooi talks about the best but tricky solution to combating new variants, touches on long Covid and tells us what to note about the different vaccines used here.  Listen to Pt 1: Why bother about asymptomatic Covid-19 cases, says vaccine expert - https://omny.fm/shows/health-check-1/health-check-ep-68-p1-mixdown Produced by: Joyce Teo (joyceteo@sph.com.sg), Ernest Luis & Penelope Lee Edited by: Hadyu Rahim & Penelope Lee Subscribe to Health Check Podcast channel, hear the latest episodes every first and third Wednesday of the month and rate us on your favourite audio apps: Channel: https://str.sg/JWaN Apple Podcasts: https://str.sg/JWRX Spotify: https://str.sg/JWaQ Google Podcasts: https://str.sg/J6Wv  Website: http://str.sg/stpodcasts Feedback to: podcast@sph.com.sg Read Joyce Teo's stories: https://str.sg/JbxN --- Discover more ST podcast series: Green Pulse Podcast: https://str.sg/JWaf Health Check Podcast: https://str.sg/JWaN ST Sports Talk Podcast: https://str.sg/JWRE Life Weekend Picks Podcast: https://str.sg/JWa2 #PopVultures Podcast: https://str.sg/JWad Bookmark This! Podcast: https://str.sg/JWas Lunch With Sumiko Podcast: https://str.sg/J6hQ Discover BT Podcasts: https://bt.sg/pcPL Follow our shows then, if you like short, practical podcasts! See omnystudio.com/listener for privacy information.

Health Check Ep 68 (Pt 2): Vaccine expert on combating new Covid variants 20:02 mins Synopsis: Every first and third Wednesday of the month, The Straits Times helps you make sense of health matters that affect you. In this episode, ST senior health correspondent Joyce Teo speaks with Prof Ooi Eng Eong from the Duke-NUS Medical School's Programme in Emerging Infectious Diseases about the current Covid-19 situation and how vaccination will lead us out of this pandemic. In the second part of their conversation, Prof Ooi talks about the best but tricky solution to combating new variants, touches on long Covid and tells us what to note about the different vaccines used here.  Listen to Pt 1: Why bother about asymptomatic Covid-19 cases, says vaccine expert - https://omny.fm/shows/health-check-1/health-check-ep-68-p1-mixdown Produced by: Joyce Teo (joyceteo@sph.com.sg), Ernest Luis & Penelope Lee Edited by: Hadyu Rahim & Penelope Lee Subscribe to Health Check Podcast channel, hear the latest episodes every first and third Wednesday of the month and rate us on your favourite audio apps: Channel: https://str.sg/JWaN Apple Podcasts: https://str.sg/JWRX Spotify: https://str.sg/JWaQ Google Podcasts: https://str.sg/J6Wv  Website: http://str.sg/stpodcasts Feedback to: podcast@sph.com.sg Read Joyce Teo's stories: https://str.sg/JbxN --- Discover more ST podcast series: Green Pulse Podcast: https://str.sg/JWaf Health Check Podcast: https://str.sg/JWaN ST Sports Talk Podcast: https://str.sg/JWRE Life Weekend Picks Podcast: https://str.sg/JWa2 #PopVultures Podcast: https://str.sg/JWad Bookmark This! Podcast: https://str.sg/JWas Lunch With Sumiko Podcast: https://str.sg/J6hQ Discover BT Podcasts: https://bt.sg/pcPL Follow our shows then, if you like short, practical podcasts! See omnystudio.com/listener for privacy information.

Singapore is one of the world's most vaccinated countries but the unvaccinated remain at risk with every infection surge. Is it time to stop persuading people and consider mandates especially for those without legitimate medical reasons? Could a sharper differentiation of measures for the unvaccinated nudge more to get the shot? And what are the drawbacks of making COVID-19 vaccination compulsory? Lin Suling gets answers from David Lye, Director of the Infectious Disease Research and Training Office at NCID, and Ashley St John, Associate Professor at Duke-NUS Medical School's Programme in Emerging Infectious Diseases. See omnystudio.com/listener for privacy information.

Health Check Ep 68 (Pt 1): Why bother about asymptomatic Covid-19 cases, says vaccine expert 19:05 mins Synopsis: Every first and third Wednesday of the month, The Straits Times helps you make sense of health matters that affect you. In this episode, ST senior health correspondent Joyce Teo speaks with Prof Ooi Eng Eong from the Duke-NUS Medical School's Programme in Emerging Infectious Diseases about the current Covid-19 situation and how vaccination will lead us out of this pandemic. He talks about the futility of reporting unlinked or even asymptomatic cases, how Covid herd immunity is a myth, and what we can learn from past dengue outbreaks, and more. Listen to Pt 2: Vaccine expert on combating new Covid variants - https://omny.fm/shows/health-check-1/vaccine-expert-on-combating-new-covid-variants-hea Produced by: Joyce Teo (joyceteo@sph.com.sg), Ernest Luis & Penelope Lee Edited by: Hadyu Rahim & Penelope Lee Subscribe to Health Check Podcast channel, hear the latest episodes every first and third Wednesday of the month and rate us on your favourite audio apps: Channel: https://str.sg/JWaN Apple Podcasts: https://str.sg/JWRX Spotify: https://str.sg/JWaQ Google Podcasts: https://str.sg/J6Wv  Website: http://str.sg/stpodcasts Feedback to: podcast@sph.com.sg Read Joyce Teo's stories: https://str.sg/JbxN --- Discover more ST podcast series: Green Pulse Podcast: https://str.sg/JWaf Health Check Podcast: https://str.sg/JWaN ST Sports Talk Podcast: https://str.sg/JWRE Life Weekend Picks Podcast: https://str.sg/JWa2 #PopVultures Podcast: https://str.sg/JWad Bookmark This! Podcast: https://str.sg/JWas Lunch With Sumiko Podcast: https://str.sg/J6hQ Discover BT Podcasts: https://bt.sg/pcPL Follow our shows then, if you like short, practical podcasts! See omnystudio.com/listener for privacy information.

Health Check Ep 68 (Pt 1): Why bother about asymptomatic Covid-19 cases, says vaccine expert 19:05 mins Synopsis: Every first and third Wednesday of the month, The Straits Times helps you make sense of health matters that affect you. In this episode, ST senior health correspondent Joyce Teo speaks with Prof Ooi Eng Eong from the Duke-NUS Medical School's Programme in Emerging Infectious Diseases about the current Covid-19 situation and how vaccination will lead us out of this pandemic. He talks about the futility of reporting unlinked or even asymptomatic cases, how Covid herd immunity is a myth, and what we can learn from past dengue outbreaks, and more. Listen to Pt 2: Vaccine expert on combating new Covid variants - https://omny.fm/shows/health-check-1/vaccine-expert-on-combating-new-covid-variants-hea Produced by: Joyce Teo (joyceteo@sph.com.sg), Ernest Luis & Penelope Lee Edited by: Hadyu Rahim & Penelope Lee Subscribe to Health Check Podcast channel, hear the latest episodes every first and third Wednesday of the month and rate us on your favourite audio apps: Channel: https://str.sg/JWaN Apple Podcasts: https://str.sg/JWRX Spotify: https://str.sg/JWaQ Google Podcasts: https://str.sg/J6Wv  Website: http://str.sg/stpodcasts Feedback to: podcast@sph.com.sg Read Joyce Teo's stories: https://str.sg/JbxN --- Discover more ST podcast series: Green Pulse Podcast: https://str.sg/JWaf Health Check Podcast: https://str.sg/JWaN ST Sports Talk Podcast: https://str.sg/JWRE Life Weekend Picks Podcast: https://str.sg/JWa2 #PopVultures Podcast: https://str.sg/JWad Bookmark This! Podcast: https://str.sg/JWas Lunch With Sumiko Podcast: https://str.sg/J6hQ Discover BT Podcasts: https://bt.sg/pcPL Follow our shows then, if you like short, practical podcasts! See omnystudio.com/listener for privacy information.

With one of the world's highest vaccination rates and the ability to quickly test for COVID-19 infections, some questions were raised this week when the Singapore Government said it would not rule out a circuit breaker as it navigates a path towards opening up further. Is it possible to have a clean, clear exit strategy from the pandemic? And how close is Singapore to being able to live normally with an endemic COVID-19? CNA's Lin Suling speaks to Associate Professor Lim Poh Lian, member of the Expert Committee on COVID-19 Vaccination, and Professor Ooi Eng Eong of the Programme in Emerging Infectious Diseases at Duke-NUS Medical School. See omnystudio.com/listener for privacy information.

Mark Goh and Shu-Ling Chong, Duke-NUS Medical School and KK Women's and Children's Hospital, Singapore joins editor Colin Mahoney to discuss their systematic review and meta-analysis spanning 6000 articles dealing with neurocognitive outcomes following traumatic brain injury (TBI) in children. They highlight how dose of TBI impacts executive function and memory with potentially long term impacts. https://jnnp.bmj.com/content/92/8/847

The Big Story Ep 87: Making sense of Singapore's new Covid-19 clusters 5:50 mins Synopsis: This is a special episode of The Straits Times' video series The Big Story, hosted by Hairianto Diman and Olivia Quay. The Health Ministry on Monday announced 19 new Covid-19 cases, including three in the community. Of the three cases, two work in Changi Airport Terminal 3 and are linked to the Changi Airport cluster. Professor Eric Finkelstein, from the Health Services and Systems Research Programme at Duke-NUS Medical School, weighs in on the emergence of new Covid-19 clusters here. Produced by: Hairianto Diman (mdhairi@sph.com.sg) & Olivia Quay (oliviaq@sph.com.sg) Edited by: ST Video team and Aleemah Basirah Discover The Straits Times Videos: https://str.sg/JPrc Discover ST podcasts: Channel: https://str.sg/JWVR Spotify: https://spoti.fi/2PwZCYU Apple Podcasts: https://apple.co/2Lu4rPP Google podcasts: http://str.sg/googlestbt Websites: http://str.sg/stbtpodcasts Feedback to: podcast@sph.com.sg  Follow Hairianto Diman on Instagram: https://www.instagram.com/iamhairianto/?hl=en Follow Olivia Quay on Instagram: https://www.instagram.com/oliviaquayhere/?hl=en --- Discover more ST podcast series: Asian Insider Podcast: https://str.sg/JWa7 Green Pulse Podcast: https://str.sg/JWaf Health Check Podcast: https://str.sg/JWaN ST Sports Talk Podcast: https://str.sg/JWRE Life Weekend Picks Podcast: https://str.sg/JWa2 #PopVultures Podcast: https://str.sg/JWad Bookmark This! Podcast: https://str.sg/JWas Lunch With Sumiko Podcast: https://str.sg/J6hQ Discover BT Podcasts:  http://bt.sg/podcasts Follow our shows then, if you like short, practical podcasts! See omnystudio.com/listener for privacy information.

In this edition, The Straits Times' assistant video editor Olivia Quay and multimedia journalist Hairianto Dirman spoke to Dr. Eric Finkelstein, Professor of Health Services and Systems Research at the Duke-NUS Medical School, about the latest update on Covid-19 clusters in Singapore. See omnystudio.com/listener for privacy information.

In The Straits Times’ The Big Story, assistant video editor Olivia Quay and multimedia journalist Hairianto Dirman spoke to Professor Ooi Eng Eong, from the emerging infectious diseases programme at Duke-NUS Medical School about the possibility of Covid-19 vaccine mixing. See omnystudio.com/listener for privacy information.

Pour cette semaine du 22 mars : des nouvelles concernant l'immunité au coronavirus, une intrigante anomalie détectée au Cern, des mesures inédites du noyau de Mars, un traitement encourageant pour les malades d'Alzheimer et une carte des espèces qui demeurent à découvrir. Bonne écoute, et bon week-end !

In The Straits Times’ The Big Story, multimedia journalist Hairianto Dirman and assistant video editor Olivia Quay spoke to Dr Ruklanthi de Alwis, a senior fellow from the Emerging Infectious Diseases Programme, at Duke-NUS Medical School about Singapore's vaccination progress. See omnystudio.com/listener for privacy information.

We’ve been warned that pandemics like COVID-19 will become more common, and each one possibly worse than before. But what might the next pandemic look like? We are joined by Prof Wang Linfa, Director of the Programme in Emerging Infectious Diseases at the Duke-NUS Medical School in Singapore to discuss what we can learn from past pandemics, and how we can be better prepared for the next. With reports that coronaviruses related to SARS-CoV-2 may be found in bats across Asia, Prof Wang also shares why bats are often the reservoirs for zoonotic pathogens, but why they are not to blame for the COVID-19 pandemic and past outbreaks. Image source: Shutterstock

In Health Suites, Claressa Monteiro speaks to Dr Tham Yih Chung, Senior Clinical Research Fellow, Singapore Eye Research Institute. Assistant Professor, Duke-NUS Medical School, to find out how the Singapore National Eye Centre (SNEC) and Singapore Eye Research Institute (SERI) explored the use of deep learning systems to alleviate the burden on eye care systems - and why it is important that AI is introduced into the medical work. See omnystudio.com/listener for privacy information.

Two weeks before Chinese New Year, what’s behind Singapore’s new restrictions? What is the outlook for the country’s COVID-19 fight amid a raging pandemic, new mutated variants and rising imported cases? And are there conditions under which the rules can be peeled back as mass testing and nation-wide vaccinations get underway? Lin Suling speaks to Professor Hsu Li Yang, Vice Dean (Global Health) at the NUS Saw Swee Hock School of Public Health, and Professor of Health Services and Systems Research David B Matchar from the Duke-NUS Medical School. See omnystudio.com/listener for privacy information.

The Big Story Ep 71: Covid-19 vaccines likely still effective against variants 4:03 mins Synopsis: This is a special episode of The Straits Times' video series The Big Story. Covid-19 vaccines like the Pfizer-BioNTech version being used in Singapore are likely to remain effective against new variants of the coronavirus, including recent strains detected in Britain and South Africa. Professor Ooi Eng Eong, deputy director of the emerging infectious diseases programme at Duke-NUS Medical School, shares more with hosts Olivia Quay and Hairianto Diman. Produced and edited by: ST Video team and Muhammad Firmann Discover The Straits Times Videos: https://str.sg/JPrc Discover ST & BT podcasts: Channel: https://str.sg/JWVR Spotify: https://spoti.fi/2PwZCYU Apple Podcasts: https://apple.co/2Lu4rPP Google podcasts: http://str.sg/googlestbt Websites: http://str.sg/stbtpodcasts https://bt.sg/moneyhacks Feedback to: podcast@sph.com.sg  --- Discover more niche podcast series by ST and BT below: Follow BT Money Hacks Podcast on: http://bt.sg/btmoneyhacks Follow BT Mark To Market Podcast on: http://bt.sg/btmark2mkt Follow Health Check Podcast on: https://str.sg/JWaN Follow Green Pulse Podcast on: https://str.sg/JWaf Follow Asian Insider Podcast on: https://str.sg/JWa7 Follow Lunch With Sumiko Podcast on: https://str.sg/J6hQ Follow #PopVultures Podcast on: https://str.sg/JWad Follow Life Weekend Picks Podcast on: https://str.sg/JWa2 Follow #GameOfTwoHalves Podcast on: https://str.sg/JWRE Follow Bookmark This! Podcast on: https://str.sg/JWas Follow our shows then, if you like short, practical podcasts! See omnystudio.com/listener for privacy information.

In The Straits Times’ The Big Story, multimedia correspondent Harianto Dirman and assistant video editor Olivia Quay spoke to infectious diseases expert, Ooi Eng Eong from the Duke-NUS Medical School to find out why experts believe Covid-19 vaccines are likely to remain effective against new variants of the coronavirus. See omnystudio.com/listener for privacy information.

Health Check Ep 52: Addressing Covid-19 vaccine safety and the science behind it 20:14 mins Synopsis: This is a fortnightly podcast series on Wednesdays by The Straits Times and this episode is on the safety of Covid-19 vaccines. Much has been said about the safety and effectiveness of the Covid-19 vaccine frontrunners but there are still many people who are hesitant about taking the vaccine, mostly because they are unsure if it is truly safe. In this episode, ST senior health correspondent Joyce Teo hosts Prof Ooi Eng Eong from the Duke-NUS Medical School. He's the school's principal investigator in the partnership with Arcturus Therapeutics to develop a self-replicating mRNA Covid-19 vaccine. Prof Ooi talks about the science of the vaccine, addresses concerns about side effects (including reports of long-term effects from pandemic flu jabs), as well as discuss the Pfizer-BioNTech and Moderna mRNA vaccines, and how different the one being trialled here is. Produced by: Joyce Teo (joyceteo@sph.com.sg), Penelope Lee and Ernest Luis  Edited by: Penelope Lee Subscribe to Health Check Podcast channel, hear the latest episodes fortnightly on Wednesdays and rate us on your favourite audio apps: Channel: https://str.sg/JWaN Apple Podcasts: https://str.sg/JWRX Spotify: https://str.sg/JWaQ Google Podcasts: https://str.sg/J6Wv  Website: http://str.sg/stpodcasts Feedback to: podcast@sph.com.sg Read her stories: https://str.sg/JbxN --- Discover more ST podcast series: Asian Insider Podcast: https://str.sg/JWa7 Green Pulse Podcast: https://str.sg/JWaf ST Sports Talk Podcast: https://str.sg/JWRE Life Weekend Picks Podcast: https://str.sg/JWa2 #PopVultures Podcast: https://str.sg/JWad Bookmark This! Podcast: https://str.sg/JWas Lunch With Sumiko Podcast: https://str.sg/J6hQ Discover BT Podcasts:  http://bt.sg/podcasts Follow our shows then, if you like short, practical podcasts! See omnystudio.com/listener for privacy information.

Health Check Ep 52: Addressing Covid-19 vaccine safety and the science behind it 20:14 mins Synopsis: This is a fortnightly podcast series on Wednesdays by The Straits Times and this episode is on the safety of Covid-19 vaccines. Much has been said about the safety and effectiveness of the Covid-19 vaccine frontrunners but there are still many people who are hesitant about taking the vaccine, mostly because they are unsure if it is truly safe. In this episode, ST senior health correspondent Joyce Teo hosts Prof Ooi Eng Eong from the Duke-NUS Medical School. He's the school's principal investigator in the partnership with Arcturus Therapeutics to develop a self-replicating mRNA Covid-19 vaccine. Prof Ooi talks about the science of the vaccine, addresses concerns about side effects (including reports of long-term effects from pandemic flu jabs), as well as discuss the Pfizer-BioNTech and Moderna mRNA vaccines, and how different the one being trialled here is. Produced by: Joyce Teo (joyceteo@sph.com.sg), Penelope Lee and Ernest Luis  Edited by: Penelope Lee Subscribe to Health Check Podcast channel, hear the latest episodes fortnightly on Wednesdays and rate us on your favourite audio apps: Channel: https://str.sg/JWaN Apple Podcasts: https://str.sg/JWRX Spotify: https://str.sg/JWaQ Google Podcasts: https://str.sg/J6Wv  Website: http://str.sg/stpodcasts Feedback to: podcast@sph.com.sg Read her stories: https://str.sg/JbxN --- Discover more ST podcast series: Asian Insider Podcast: https://str.sg/JWa7 Green Pulse Podcast: https://str.sg/JWaf ST Sports Talk Podcast: https://str.sg/JWRE Life Weekend Picks Podcast: https://str.sg/JWa2 #PopVultures Podcast: https://str.sg/JWad Bookmark This! Podcast: https://str.sg/JWas Lunch With Sumiko Podcast: https://str.sg/J6hQ Discover BT Podcasts:  http://bt.sg/podcasts Follow our shows then, if you like short, practical podcasts! See omnystudio.com/listener for privacy information.

Dr. Sandra Boesch worked for IBM for 10 years, for Duke-NUS Medical School in Singapore, and has lived on 3 continents. She recently repatriated to Arizona in the US. She has worked in communications, marketing, public relations, software product management, sales enablement, and education technologies. She has worked as a worldwide manager and lived in Latin America, Asia, and North America. She love cultures and cultural differences. She believes and is excited about continued education. She holds a BS in Communications, an MBA with specializations in finance and marketing, an MIS, and a Ph.D. in Information systems plus several other certificates. She is bilingual, speaking English and Spanish, and spent 13 years living and working in Singapore with her husband and two kids. Stay In Touch: Connect on Facebook and Instagram with thoughts, questions, and feedback. Rate, review and share this podcast with anyone that would love to listen. Find Us Online: @aworldof.difference on Instagram and A World of Difference on Facebook --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app (https://anchor.fm/app) Support this podcast: https://anchor.fm/lori-adams-brown/support (https://anchor.fm/lori-adams-brown/support)Mentioned in this episode: Coaching Sept 22 Want to get unstuck and make a difference? Go to loriadamsbrown.com/coachnig for a free exploratory session. Patreon Support us for as little as $5/month at Patreon.com/aworldofdifference and receive exclusive audio content and free merch. This podcast uses the following third-party services for analysis: Podcorn - https://podcorn.com/privacy

Dr. Sandra Boesch worked for IBM for 10 years, for Duke-NUS Medical School in Singapore, and has lived on 3 continents. She recently repatriated to Arizona in the US. She has worked in communications, marketing, public relations, software product management, sales enablement, and education technologies. She has worked as a worldwide manager and lived in Latin America, Asia, and North America. She love cultures and cultural differences. She believes and is excited about continued education. She holds a BS in Communications, an MBA with specializations in finance and marketing, an MIS, and a Ph.D. in Information systems plus several other certificates. She is bilingual, speaking English and Spanish, and spent 13 years living and working in Singapore with her husband and two kids. Stay In Touch: Connect on Facebook and Instagram with thoughts, questions, and feedback. Rate, review and share this podcast with anyone that would love to listen. Find Us Online: @aworldof.difference on Instagram and A World of Difference on Facebook --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/lori-adams-brown/supportMentioned in this episode:Do you want to go deeper?Join us in Difference Makers, a community where we watch and discuss exclusive content that truly makes a difference. Give us $5 a month (the price of a latte), and join in on the conversation with our host Lori and others who want to make a difference. We'd love to have you join us!PatreonJoin Difference MakersJoin us in our membership community for exclusive content for only $5/month at https://www.patreon.com/aworldofdifference. We go deeper with each guest, and it makes such a difference.PatreonThis podcast uses the following third-party services for analysis: Chartable - https://chartable.com/privacyPodtrac - https://analytics.podtrac.com/privacy-policy-gdrp

Dr. Sandra Boesch worked for IBM for 10 years, for Duke-NUS Medical School in Singapore, and has lived on 3 continents. She recently repatriated to Arizona in the US. She has worked in communications, marketing, public relations, software product management, sales enablement, and education technologies. She has worked as a worldwide manager and lived in Latin America, Asia, and North America. She love cultures and cultural differences. She believes and is excited about continued education. She holds a BS in Communications, an MBA with specializations in finance and marketing, an MIS, and a Ph.D. in Information systems plus several other certificates. She is bilingual, speaking English and Spanish, and spent 13 years living and working in Singapore with her husband and two kids. Stay In Touch: Connect on Facebook and Instagram with thoughts, questions, and feedback. Rate, review and share this podcast with anyone that would love to listen. Find Us Online: @aworldof.difference on Instagram and A World of Difference on Facebook --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app (https://anchor.fm/app) Support this podcast: https://anchor.fm/lori-adams-brown/support (https://anchor.fm/lori-adams-brown/support)Mentioned in this episode: Coaching Sept 22 Want to get unstuck and make a difference? Go to loriadamsbrown.com/coachnig for a free exploratory session. Patreon Support us for as little as $5/month at Patreon.com/aworldofdifference and receive exclusive audio content and free merch. This podcast uses the following third-party services for analysis: Podcorn - https://podcorn.com/privacy

Dr. Sandra Boesch worked for IBM for 10 years, for Duke-NUS Medical School in Singapore, and has lived on 3 continents. She recently repatriated to Arizona in the US. She has worked in communications, marketing, public relations, software product management, sales enablement, and education technologies. She has worked as a worldwide manager and lived in Latin America, Asia, and North America. She love cultures and cultural differences. She believes and is excited about continued education. She holds a BS in Communications, an MBA with specializations in finance and marketing, an MIS, and a Ph.D. in Information systems plus several other certificates. She is bilingual, speaking English and Spanish, and spent 13 years living and working in Singapore with her husband and two kids. Stay In Touch: Connect on Facebook and Instagram with thoughts, questions, and feedback. Rate, review and share this podcast with anyone that would love to listen. Find Us Online: @aworldof.difference on Instagram and A World of Difference on Facebook --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/lori-adams-brown/supportMentioned in this episode:Do you want to go deeper?Join us in Difference Makers, a community where we watch and discuss exclusive content that truly makes a difference. Give us $5 a month (the price of a latte), and join in on the conversation with our host Lori and others who want to make a difference. We'd love to have you join us!PatreonJoin Difference MakersJoin us in our membership community for exclusive content for only $5/month at https://www.patreon.com/aworldofdifference. We go deeper with each guest, and it makes such a difference.PatreonThis podcast uses the following third-party services for analysis: Chartable - https://chartable.com/privacyPodtrac - https://analytics.podtrac.com/privacy-policy-gdrp

Senior Research Fellow at Duke-NUS Medical School, Dr. Anthony Tanoto Tan, discusses his work in the field of immunopathology as it relates to both hepatitis B and the SARS-CoV-2 virus responsible for the COVID-19 situation. In this episode, you will learn: What role T cells play in the immune response to infectious diseases, and how they store “memory” of certain pathogens How T cells differ from antibodies, in general and in the context of COVID-19 What it might mean that people who have never been exposed to the SARS-coV-2 virus have specific T cells for it For the past 10 to 15 years, Dr. Tan has been trying to understand the immune system response to disease, and its role in clearing infectious diseases. With a special focus on hepatitis B, which causes an infection and can proceed to liver cancer, he ended up researching adaptive T-cell therapy for liver cancer. With expertise in the analysis of virus-specific T cells, Dr. Tan and his team began researching the T cell response to the SARS-CoV-2 virus with the goal of determining whether there are differences in the immune response in people who are asymptomatic or have a mild case of the virus, and people who develop severe symptoms. They are also trying to understand how the T cell response changes over time, from the acute phase of the infection through to resolution of the infection. Dr. Tan discusses the details of his recent publication on this research, which shows that people who were infected with SARS-CoV-1 17 years ago still have SARS-CoV-1-specific T cells. Not surprisingly, SARS-CoV-2-specific T cells were found in individuals who have been infected with SARS-CoV-2. Of particular interest is the finding that people who have NOT been exposed to either virus were shown to have SARS-CoV-2-specific T cells. This suggests that a proportion of unexposed individuals have a preexisting immune response to the virus that's causing COVID-19. Whether the function of this immune response is protective is the question that remains.   In addition to these topics, Dr. Tan talks about the processes in innate and adaptive immunity, how T cells behave during pathogenesis, what causes T cells to have a faster response to infected cells, which proteins to target with a vaccination, and much more. Available on Apple Podcasts: apple.co/2Os0myK

Korea24 – 2020.08.25. (Tuesday) - News Briefing: Kindergartens and schools in the greater Seoul area will shift to online classes from Wednesday as we continue to see hundreds of COVID-19 cases added each day. The measure is to continue until September 11, at which time the government will decide whether to extend it taking into account the overall situation. (Robert Koehler) - In-Depth News Analysis: Professor Linfa Wang, director of the Emerging Infectious Diseases Programme at Duke-NUS Medical School, delves into the resurgence of COVID-19 cases in both South Korea and abroad and gives his thoughts on what could bring an end to the coronavirus pandemic. - Korea Trending with Lee Ju-young: The CSAT is just 100 days away amid the pandemic and the possibility of social distancing measures being raised to Level 3(수능100일), the health ministry clarifies the admissions process for public medical schools(공공의대), and K-pop legend BoA celebrates 20 years in the industry(보아, 데뷔 20주년). - Touch Base in Seoul: Diana Berrent, COVID-19 survivor and founder of Survivor Corps, shares how the organization connects COVID-19 survivors with the medical and scientific community in efforts to help with post-recovery issues such as negative aftereffects from the virus. - Morning Edition Preview with Mark Wilson-Choi: The Korea Herald has a story that features the original Korean opera "Red Pants" that focuses on South Korea's housing bubble, and the Korea Times has a piece that features four foreign female entrepreneurs and their upcoming discussion panel.

In The Straits Times The Big Story, the first batch of volunteers have been dosed with a Covid-19 vaccine developed locally by Duke-NUS Medical School and US firm Arcturus Therapeutics. ST’s multimedia correspondent Hairianto Dirman and assistant video editor Olivia Quay spoke to the unit's deputy clinical and scientific director, Associate Professor Jenny Low on the trial process and when this vaccine can be made available to the masses if it is found to be effective. See omnystudio.com/policies/listener for privacy information.

The model of teaching is quickly adapting and changing in the face of global changes. But were those changes already underway before COVID-19? Prof Ian Curran, Vice Dean, Education at Duke-NUS Medical School, sits down with QS to discuss the principles behind digital transformation and reveals some surprising truths about online. Can an orange be a better educational tool than technology?

Moderna, Pfizer and over 100 pharmaceutical firms and research institutes are racing towards developing the first coronavirus vaccine. Lin Suling speaks to the World Health Organization’s (WHO) Jacqueline Ying-Ru Lo and Duke-NUS Medical School's Professor Ooi Eng Eong who is involved in human trials in Singapore, to find out when and how a vaccine will move from labs to patients. They also get to the bottom of who should get priority and how that will be decided. See omnystudio.com/listener for privacy information.

“How do you do the process of regulation? Not the science of regulation, but how do you do the process of regulation more flexibly and agilely?” asks Murray Lumpkin, Deputy Director Integrated Development and Lead for Global Regulatory Systems Initiatives, Bill & Melinda Gates Foundation. “We certainly hope that the openness that regulators around the world have to this concept of reliance, of referencing, will evolve and strengthen because of what we're all going through now,” says John Lim, founding Executive Director of the Center of Regulatory Excellence at Duke-NUS Medical School in Singapore. (Listen to our previous Pandemic Vaccine Preparedness podcast with Dr. Lumpkin.)

Talk about a masterclass. We talk to the man who discovered the bat-to-man link of the SARS virus back in 2003 and is currently deeply involved in getting to the bottom of the ongoing pandemic. Professor Wang Linfa, Director of the Programme in Emerging Infectious Diseases at Duke-NUS Medical School, walks us through numerous questions about the coronavirus wreaking lives and livelihood worldwide. What’s the difference between SARS-COV-2 and Covid-19? Where did it originate, and could it be man-made? Why is it so infectious? Are asymptomatic carriers infectious? How good are the tests, and what’s the pipeline for rapid-tests? What about anti-bodies and convalescent plasma therapy? What’s the latest on anti-viral developments? What about the holy grail of vaccine development? You will not find a more informed set of answers! See omnystudio.com/listener for privacy information.

Glenn van Zutphen speaks to A Dr Duane J. Gubler, Founder, Director, Emerging Infectious Diseases signature research programme at Duke-NUS Medical School, Singapore about how the Covid-19 pandemic was neither an unexpected nor unpredictable black swan event as many infectious disease experts have repeatedly warned of such a possibility.

We Are Exploring: Sleep & Society - How Sleep Continues To Be An Ignored Part Of Our Lives The Bi-directional Links Between Physical & Mental Health And Sleep The Role Of Technology & What It Holds For The Future Of Sleep How The Pandemic Is Going To Change Our Sleep Health Dr. Amiya Patanaik is the CEO & Co-founder of Neurobit Technologies. He has a PhD in Computer Engineering from NTU Singapore. A deep tech start-up working on making high quality sleep health, accessible and affordable. He has been studying machine-learning and AI with applications to cognitive neuroscience and medical signals for more than a decade. Amiya has authored two international patents and his work has been published in high impact scientific journals including Nature, Proceedings of National Academy of Science, Neuroimage, Sleep, ACM and IEEE. Before starting Neurobit, he was working on improving sleep and memory using real-time acoustic stimulations as a post-doc at Duke-NUS Medical School. 0.29 - Sleep Health Studies 2.32 - Recommended Amount Of Sleep 3.04 - Physical, Emotional & Mental Health 3.58 - Deep Sleep Explained 5.02 - Neuroscience Of Prayer & Meditation 7.23- Can Positive Thinking & Lockdown Impact Sleep 8.50 - Nuerobit & Wearables Technology 12.06 - Sleep Apnea Or Loud Snoring 13.42 - Sleep Studies vs Nuerobit 15.30 - Piloting Sleep Apnea 16.53 - The Pandemic Changing Sleep Health 18.24 - Technology In The Future Of Sleep 20.55 - What Disrupts Our Sleep? 25.11- 4 Tips To Instantly Improve Your Sleep                

ThinkTech is a Hawaii 501(c)(3) nonprofit. Please support us by making a donation. http://www.thinktechhawaii.com How much do we really know about it?. Dr. Duane Gubler, world-famous infectious disease researcher, who has been with Johns Hopkins, CDC, WHO, JABSOM and finally DUKE-NUS Medical School in Singapore, will help us understand how coronavirus works, how it is transmitted and why it is so contagious, and how pandemics spread and ultimately peter out, how vaccines are developed and deployed, and what steps should best be taken now. The host for this episode is Jay Fidell. The guest for this episode is Duane Gubler.

Join Claressa Monteiro, as she speaks with Professor Wang Linfa, Director of the Emerging Infectious Disease Programme at Duke-NUS Medical School about how Singaporean scientists successfully cultured COVID-19 from an infected patient’s clinical sample. This could be the game-changer in the fight against the deadly pandemic. 

Grace Kwak is currently in her final year of undergraduate studies as a Life Sciences major at Yale-NUS College. Grace has had a special focus on research public health projects such as adolescent suicide in South Korea and vaccination confidence in Singapore. After graduating in May 2020, she will be starting medical school in Duke-NUS Medical School (https://www.linkedin.com/in/research-assistant-health/) At UNLEASH, Grace's team created a unique idea around incentivizing people in India to use bathroom. "PoopIT" seeks to create a digital credit-based system where users gain credits for using the toilets; these credits can be used to buy desired products at retail stores. The “poop card” will be a physical and digital card, linked to a digital wallet (which can be accessed by both more high-tech smartphones and simple Nokia phone users, alike). Users simply need to tap in and tap out after using the toilet to earn credits. PoopIT is planning to use a system with simple radio frequency identification technology and a time algorithm to monitor toilet usage and prevent people from tapping in & out at toilet facilities to just earn credits without actually using them. We believe that this external motivator of rewards, coupled with educational campaigns to educate people on the issue of open defecation, will instill an internal motivation to start using toilets and promote sanitation. To learn about the solution, considering viewing this link: https://unleash.org/solutions/poop-card/

[Daily News Update] Reporter: Chu Jihyun - Wuhan Coronavirus updates [Special Coronavirus Interview] Guest: Dr. Gregory Gray(Global Health Institute, Duke-NUS Medical School, Singapore) - Breakthroughs in Coronavirus Vaccine Development [Question Box] Contributor: 홍지인 - Solidarity during a National(Global) Crisis

Health Check Ep 29: Virologist Prof Wang Linfa offers hand hygiene tips to counter novel coronavirus threat 12:17 mins Synopsis: In this fortnightly podcast series on Wednesdays, The Straits Times guides you to healthier living and clears up common misconceptions on health. In this episode, ST correspondent Joyce Teo calls Professor Wang Linfa. He is the director of the emerging infectious disease programme at Duke-NUS Medical School. He is also a virologist who was part of the World Health Organization Emergency Committee on the novel coronavirus outbreak. We ask him the latest updates on the novel coronavirus, and what we can do to protect ourselves. Professor Wang tells us: How to be aware and maintain hand hygiene when using lifts and public toilets, because contact transmission for the novel coronavirus is potent (1:17) Droplet transmission threat for coronaviruses: What should you do to protect yourself better when using taxis or private hire cars for example? (4:23) Is faecal transmission possible with the novel coronavirus? (6:35) Tips for older people and those with existing conditions (7:19) One good tip on using a ballpoint pen and its cap to press lift buttons and reduce your skin's exposure to possible coronaviruses (9:41) Produced by: Joyce Teo and Ernest Luis Edited by: Penelope Lee Follow more Health Check podcasts and rate us on: Spotify: http://str.sg/oeGY Apple Podcasts: http://str.sg/oeXP Google Podcasts: http://str.sg/oeLN Playlist: https://str.sg/Jw7R Website: http://str.sg/stpodcasts Feedback to: podcast@sph.com.sg   Thank you for your support! ST and BT Podcasts picked up a silver medal for Best Digital Project to engage younger and/or millennial audiences at 2019 Asian Digital Media Awards by Wan-Ifra: https://str.sg/Jw5T

Health Check Ep 29: Virologist Prof Wang Linfa offers hand hygiene tips to counter novel coronavirus threat 12:17 mins Synopsis: In this fortnightly podcast series on Wednesdays, The Straits Times guides you to healthier living and clears up common misconceptions on health. In this episode, ST correspondent Joyce Teo calls Professor Wang Linfa. He is the director of the emerging infectious disease programme at Duke-NUS Medical School. He is also a virologist who was part of the World Health Organization Emergency Committee on the novel coronavirus outbreak. We ask him the latest updates on the novel coronavirus, and what we can do to protect ourselves. Professor Wang tells us: How to be aware and maintain hand hygiene when using lifts and public toilets, because contact transmission for the novel coronavirus is potent (1:17) Droplet transmission threat for coronaviruses: What should you do to protect yourself better when using taxis or private hire cars for example? (4:23) Is faecal transmission possible with the novel coronavirus? (6:35) Tips for older people and those with existing conditions (7:19) One good tip on using a ballpoint pen and its cap to press lift buttons and reduce your skin's exposure to possible coronaviruses (9:41) Produced by: Joyce Teo and Ernest Luis Edited by: Penelope Lee Follow more Health Check podcasts and rate us on: Spotify: http://str.sg/oeGY Apple Podcasts: http://str.sg/oeXP Google Podcasts: http://str.sg/oeLN Playlist: https://str.sg/Jw7R Website: http://str.sg/stpodcasts Feedback to: podcast@sph.com.sg   Thank you for your support! ST and BT Podcasts picked up a silver medal for Best Digital Project to engage younger and/or millennial audiences at 2019 Asian Digital Media Awards by Wan-Ifra: https://str.sg/Jw5T See omnystudio.com/listener for privacy information.

Coronavirus updates Guests: Professor Linfa Wang, Emerging Infectious Disease, Duke-NUS Medical School

Join Claressa Monteiro, as she speaks to Professor Ooi Eng Eong, Deputy Director, Emerging Infectious Diseases Programme, Duke-NUS Medical School about the existence of flu in our modern society, how the risks associated with the infection are best managed and the available treatments.

  Dr. Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the journal and its editors. We're your cohosts. I'm Dr. Carolyn Lam, Associate Editor from the National Heart Center, and Duke National University of Singapore. Dr. Greg Hundley: And I'm Greg Hundley, associate editor from the Poly Heart Center at VCU health in Richmond, Virginia. Dr. Carolyn Lam: Greg, I'm so excited about the feature paper this week. You know it deals with machine learning. It's such a hot topic now, and this one particularly deals with machine learning and the prediction of the likelihood of an acute myocardial infarction. So everyone's going to want to listen to it. Let's discuss a couple of papers and get to it, shall we? Dr. Greg Hundley: Absolutely Carolyn, would you like to go first? Dr. Carolyn Lam: I sure would. So my first pick is the first study to investigate the overall importance of translational regulatory networks in myocardial fibrosis. This is the study from doctors Rackham and Cook from Duke NUS Medical School here in Singapore. Dr. Carolyn Lam: What they did is they generated nucleotide resolution translatome data during transforming growth factor beta one, or TGF beta one-driven cellular transition of human cardiac fibroblasts to myofibroblasts. So this technique identified the dynamic changes of RNA transcription and translation at several time points during the fibrotic response, revealing transient and early responder genes. Dr. Carolyn Lam: Now, very remarkably about one third of all the changes in gene expression in activated fibroblasts was subject to translational regulation and dynamic variation in the ribosome occupancy, affected protein abundance independent of RNA levels. Ribosome occupancy in the hearts of patients with dilated cardiomyopathy suggest that the same post-transcriptional regulatory network, which was underlying cardiac fibrosis. Now key network hubs included RNA binding proteins such as PUM2 and QKI that worked in concert to regulate the translation of target transcripts in the human disease hearts. Dr. Carolyn Lam: Furthermore, the authors showed that silencing of both PUM2 and QKI inhibited the transition of fibroblasts towards profibrotic myofibroblast in response to TGF beta one. Dr. Greg Hundley: You know, Carolyn, this whole aspect of fibroblasts and how they turn on and turn off, become myofibroblasts, such a hot topic in heart failure. What are the clinical implications of this work? Dr. Carolyn Lam: Yes, I agree. Well, threefold. First, these authors identified previously unappreciated genes under translational control, which could be novel candidates for disease biology and therapeutic targets. Dr. Carolyn Lam: Number two, they found that critical fibrosis factors impacted cellular phenotypes at a protein level only, and hence these cannot be appreciated using single cell, or bulk RNA sequencing approaches. So that was significant. Finally, RNA binding proteins was shown to be central to the fibrotic response and represent unexplored gene expression regulators, and of course potential diagnostic or therapeutic targets. Dr. Greg Hundley: Very nice Carolyn. Well, my next paper is also from the world of basic science, and it comes from Dr. Joseph Hill. Have we ever heard of him? Well of course, he's our Editor in Chief. He's going to discuss, he and his team investigated Polycycstin-1. Well, what is Polycycstin-1? It's a trans membrane protein, originally identified in autosomal dominant polycystic kidney disease, where it regulates the calcium permeate cation channel polycystin-2. So autosomal dominant, polycystic kidney disease patients develop renal failure, hypertension, left ventricular hypertrophy, atrial fibrillation and other cardiovascular disorders. These individuals harbor PC1 loss of function mutations in their cardiomyocytes, but the functional consequences of this are relatively unknown. Dr. Greg Hundley: Now PC1 is ubiquitously expressed in its experimental ablation in cardiomyocyte specific knockout mice reduces contractile function, and in this paper the authors set out to determine the pathophysiologic role of PC1 in these cardiomyocytes. Dr. Carolyn Lam: Huh--very interesting. I liked the way you laid that out. So what did they find? Dr. Greg Hundley: What the investigators identified is that PC1 ablation reduced action potential duration in cardiomyocytes. They decreased calcium transients and therefore myocyte contractility. PC1 deficient cardiomyocytes manifested a reduction in sarcoplasmic reticulum calcium stores due to reduced action potential duration and circa activity, an increase in outward potassium currents decreased action potential durations in cardiomyocytes lacking PC1. PC1 coimmunoprecipitated with a potassium 4.3 channel and modeled PC1 C terminal structure suggested the existence of two docking sites for PC1 within the end terminus of K4.3. Supporting a physical interaction between the cells. Finally, a naturally occurring human mutant PC1 manifested no suppressive effects on this potassium channel activity. Thus, Carolyn, Dr Hill and colleagues' results help uncover a role for PC1 in regulating multiple potassium channels, governing membrane repolarization and alterations in circa that reduce cardiomyocyte contractility. Dr. Carolyn Lam: Oh wow. What a bonanza of really interesting papers in this week. Now my next pick is a secondary analysis of the reveal trial. It hinges on the hypothesis that was generated from prior trials that the clinical response to cholesterol ester transfer protein or CETP inhibitor therapy may differ by ADCY9 genotype. So in the current study, authors Dr. Hopewell and colleagues from Nuffield Department of Population Health, University of Oxford examine the impact of ADCY9 genotype on the response to the CETP inhibitor Anacetrapib within the reveal trial. Dr. Greg Hundley: Tell me, I've forgotten a little bit, but can you remind me a little about what was the reveal trial? Dr. Carolyn Lam: Yes, of course. So the randomized placebo controlled reveal trial actually demonstrated the clinical efficacy of the CETP inhibitor Anacetrapib among more than 30,000 patients with preexisting atherosclerotic vascular disease. Now, in the current study, among more than 19,000 genotyped individuals with European ancestry, 13% had a first major vascular event during four years median follow up. The proportional reductions in the risk of major vascular events did not differ significantly by ADCY9 genotype. Furthermore, the authors showed that there were no associations between the ADCY9 genotype and the proportional reductions in the separate components of major vascular events, or any meaningful differences in lipid response to Anacetrapib. Dr. Carolyn Lam: So in conclusion, the reveal trial being the single largest study to date to evaluate the ADCY9 pharmacogenetic interaction provided no support for the hypothesis that ADCY9 genotype is materially relevant to the clinical effects of the CETP inhibitor Anacetrapib. The ongoing dal-GenE study, however, will provide direct evidence as to whether there's any specific pharmacogenetic interaction with dalcetrapib. Dr. Greg Hundley: Oh, very good. So we've got some results coming from dal-GenE. Dr. Carolyn Lam: Mm. Dr. Greg Hundley: Well, Carolyn, my last selection relates to a paper regarding the incidence of atrial fibrillation among those that exercise, and I mean really exercise. Dr. Carolyn Lam: Ooh. Dr. Greg Hundley: So the paper comes from Dr Nicholas Svedberg from Uppsala University, and studies have revealed a higher incidence of atrial fibrillation among well trained athletes. The authors in this study aim to investigate associations of endurance training with the incidents of atrial fibrillation and stroke, and to establish potential sex differences of such associations in this cohort of endurance trained athletes. They studied all Swedish skiers, so 208,654 that completed one or more races of the 30 to 90 kilometer cross country skiing event called the Vasaloppet from 1989 through 2011, and they had a matched sample of 527,448 non-skiers, and all of the individuals were followed until their first event of either atrial fibrillation or stroke. Dr. Carolyn Lam: Wow. What an interesting and what a big study. So tell us, what are the results and especially were there any sex differences? Dr. Greg Hundley: Well, interesting that you ask about those sex and gender differences. So female skiers had a lower incidence of atrial fibrillation than female non-skiers, independent of their finishing time and the number of races, whereas male skiers had a similar incidence to that of non-skiers. Second, skiers with the highest number of races or fastest finishing times had the highest incidents of the AFib, but skiers of either sex had a lower incidence of stroke than non-skiers independent of the number of races and finishing time. Third, skiers with atrial fibrillation had a higher incidence of stroke than skiers and non-skiers without atrial fibrillation. That's true for both men and women. We would think that. Finally after one had been diagnosed with atrial fibrillation, skiers with atrial fibrillation had a lower incidence of stroke and a lower mortality compared to non-skiers with atrial fibrillation. Dr. Carolyn Lam: Very interesting. Could you sum it up for us? What's the take home? Dr. Greg Hundley: Couple things. One, female endurance athletes appear to be less susceptible to atrial fibrillation than male endurance athletes. Second, both male and female endurance athletes have a lower risk of stroke independent of their fitness level. Third, after the diagnosis of atrial fibrillation, participants in a long distance skiing event with atrial fibrillation had a 27% lower risk of stroke and a 43% lower risk of dying compared to individuals from the general population with the diagnosis of atrial fibrillation. Dr. Greg Hundley: So there's some clinical implications. Although very well trained men have a higher incidence of atrial fibrillation than less trained men, the incidence is on par with that of the general population and not related to a higher incidence of stroke at that group level. This indicates that exercise has very beneficial effects on other risk factors for stroke. Then lastly, atrial fibrillation in well trained individuals should be treated according to our other usual guidelines for the population at whole. Dr. Carolyn Lam: Wow. What a fantastic study to end our little coffee chat on, but it's time to move on to our feature discussion. Dr. Carolyn Lam: Today's feature discussion touches on super-hot topics. First of all, the perennially interesting and hot topic of the prediction of acute myocardial infarction, or should I say the more precise predictions that we can do these days. The second part of the hot topic is machine learning. Oh my goodness. This is creeping into cardiovascular medicine like never before. So I'm so glad to welcome to this discussion corresponding author of the featured paper Professor Nicholas Mills from the University of Edinburgh, as well as our Associate Editor Doctor Deborah Diercks from UT Southwestern. So welcome both, and Nick, if I could start with you, tell us about MI Cubed. Prof Nicholas Mills: First thing to say, it was a major international collaboration, involved researchers from over nine different countries and we got together to develop and test an innovative algorithm that estimates for individual patients the probability when they attend the emergency department with acute chest pain that they may or may not have had a myocardial infarction. Prof Nicholas Mills: Machine learning is a really new area in cardiovascular medicine as you say. Our algorithm called MI Cubed uses a fairly simple algorithm which is a decision tree. It takes into consideration really important patient factors such as age, sex, troponin concentration at presentation, and troponin concentration on subsequent testing, and the change in troponin in between those two tests in order to estimate or calculate the probability of the diagnosis. One of the really interesting aspects of this is it's not just an algorithm for research, it's a clinical decision support tool as well. So what we've done is taken the output from that algorithm and translated it into something that is meaningful for clinicians. We've kept it quite simple. It gives an output between zero and a hundred, which is directly proportional to the likelihood of the patient having a myocardial infarct. We also provide estimated diagnostic metrics. So sensitivities and specificities that relate to that individual patient. It's really going to change the way we think about the interpretation of cardiac troponin in clinical practice. Dr. Carolyn Lam: Indeed, and first audience please, please look up the beautiful figures of this paper. I think it summarizes it all. The algorithm shows you what MI Cubed is and then compares it to the ESC three hour algorithm, one hour algorithm. Then I love the last figure, where you actually show us that very important component that you just said. As a clinical support tool, how it's going to work. So we actually have pictures of your cell phone and showing you the pictures that you're going to get from it. So super cool. Beautiful paper. Dr. Carolyn Lam: Now I just have so much to talk about, first the machine learning bit, always sexy sounding, but a bit scary for clinicians. So I really like the fact that you broke it down to actually say what components go in so that people aren't afraid of this black box. We don't know what's going on. Is there like a set time between samples, or how does this work? Do you need to have it within a certain timing? How does that fall in? Is it a particular type of troponin, what are some of the specs of the model that a practicing clinician needs to know? Prof Nicholas Mills: Well, in order to answer that question, I might explain to you the rationale for developing it. So when you're assessing a patient in the emergency department, we all recognize in our daily practice that patients differ. So interpreting troponin has been challenging. One threshold for all may not be the right way to approach this really important clinical diagnosis. Troponin concentrations differ in men and women. They differ by age, and as a surrogate of the presence of comorbidities. They differ depending on the timing of when you take that sample and when you repeat that measurement, and that has introduced some complexity. So many interesting pathways have been developed for guidelines which try and apply fixed thresholds and fixed time points, and it's pretty tough to deliver in the real world setting of a super busy emergency department. So the premise for developing this algorithm was we wanted something that was really flexible, that recognized that patients are different, they're not all the same. Prof Nicholas Mills: That's why we went for a machine learned approach rather than a more conventional statistical model. So you asked about the specification. You can do your two troponin tests whenever you like. So I had across the 11,000 patients huge variation in the timing of samples, but that is okay for MI Cubed. If you repeat the test within an hour, two hours, three hours, six hours, it still provides the same diagnostic performance. I think that's really important. Prof Nicholas Mills: You also mentioned specification about the assay. This algorithm has been developed using a particular high sensitivity cardiac troponin assay developed by Abbott Diagnostics. It will be effective for other high sensitive troponin assays, but it's unlikely to be as effective using a contemporary assay. So if your hospital uses a contemporary or conventional cardiac troponin assay, this might not be the right algorithm for you. Dr. Carolyn Lam: Great. Thank you for breaking down the issue so beautifully and practically. It really makes me think, oh my goodness, this paper's just far more than about MI. Because you know, natriuretic peptides, you could say the same thing. A prediction of heart failure is the same thing, you know? So the whole approach is novel. Deb, could you please share your thoughts and perspectives on where this is going perhaps? Dr. Deborah Diercks: I think this study is terrific because I think it does, as Dr. Mills stated, reflect reality. We don't draw measures at zero, exactly at zero, and exactly at one and exactly at three, especially in a busy emergency department. So I think it provides flexibility to the physician and provider in using it to be able to interpret values in a world that doesn't fit complete structure like the guidelines are written out. What I find really interesting about this study, and I'd love to hear more about, is how you decided the thresholds of where low risk and high risk were cut at. It mentions by consensus, and I guess I would have loved to have been a fly on the wall to hear how those discussions went, and would love to hear more from you Dr. Mills about that. Prof Nicholas Mills: Fascinating discussions amongst all the investigators on this project as to how we would define that. The first point I would make though is we designed the algorithm to provide a continuous output, a continuous measure of risk. So your MI Cubed score is between zero and a hundred. You don't have to apply a threshold, but we are used to in clinical practice having processes that support our triage of patients, and identifying people as low risk and high risk. Therefore we felt upfront that we should evaluate specific low risk and high risk thresholds. Prof Nicholas Mills: So low-risk, we were completely unanimous on how to define that, and it was based on some really nice work done by emergency physicians in New Zealand. Martin Fan, who's the first author on this paper, surveyed many emergency physicians and asked about their acceptance of risk. They came up with the concept that an algorithm to be considered safe in emergency medicine would be acceptable if the sensitivity was greater than 99% or the negative predictive value was greater than 99.5%. Prof Nicholas Mills: So we agreed up front that we would hold our low risk thresholds to those bars. Those metrics. Where there was less agreement was how you defined high risk. That didn't surprise me hugely. The positive predictive value of troponin is one of the most controversial topics around. Most cardiologists [crosstalk 00:20:52] of troponin has been difficult for them in clinical practice because with the improvements in sensitivity we are seeing lower specificity and lower causative link to value. If I put it into context, just measuring troponin and using the 99 percentile in consecutive patients gives you a positive predictive value of around about 45 to 50% in most healthcare systems for the diagnosis of type one myocardial infarction. Therein lies the problem. So one in every two patients has an abnormal troponin result but doesn't have the condition that we have evidence based treatments for, and whom cardiologists who are often quite simplistic in their approach to the assessment of these patients know how to manage. Prof Nicholas Mills: Every second patient we don't know how to manage, and therefore we wanted an algorithm that would help us identify those patients who can go through our often guideline-based pathways and treatment pathways for acute coronary syndromes more effectively. We eventually agreed that a positive predictive value of 75% would be ideal. So three out of every four patients would have the diagnosis that we knew how to manage and treat. That was our target. We got pretty close to it in our test set. I think the actual positive predictive value at the threshold of around an MI Cubed value of 50 was 72%, so pretty effective. Certainly a lot better than relying on a kind of binary threshold such as the 99 percentile to identify high risk patients. Dr. Deborah Diercks.: Thanks for that great answer. My next question is how do you think MI Cubed is going to integrate, or will it even replace the need for other risk stratification tools that we often use the emergency departments such as TIMI or the heart score? Prof Nicholas Mills: Fabulous question. In this analysis, we haven't specifically compared the performance of MI Cubed with TIMI or heart, so my answer is going to be a little speculative. You can forgive me hopefully. Both those scores were developed prior to the widespread use of high sensitive cardiac troponin tests. I think what we've learned since the introduction of high sensitive cardiac troponin is that we're using this test as a risk stratification tool, and a lot of the power of the MI Cubed algorithm comes from the way that it identifies extremely low risk patients with very low and unchanging cardiac troponin concentrations way below the diagnostic threshold. Prof Nicholas Mills: TIMI and heart simply consider troponin as a binary test, a positive or negative test, and do not take advantage of the real power of the test to restratify patients. All the evidence to date that has compared TIMI and heart with pathways that use high sensitive troponin in this way, both to restratify and diagnose patients show that these risk tools add very little in terms of safety, but do make pathways more conservative. So they identify fewer patients that are lower risk and permit discharge of those patients. Prof Nicholas Mills: So my concern about using an algorithm like MI Cubed with an existing tool like heart is that it will undermine much of the effectiveness of this tool which identifies around about two thirds of patients as low risk. If you were to combine that with a heart score, you would reduce the effectiveness. I don't think you get a gain in performance, but further research is required to do a head to head comparison with these sorts of traditional restratification tools. Dr. Carolyn Lam: I'm so grateful for this discussion, both Nick and Deb. In fact, I was about to ask what are the next steps and I think Nick you just articulated it. Deb, I want to leave the final words to you. Do you have anything else to add? Dr. Deborah Diercks: I think this study represents a real change in how we can practice medicine, where we can actually take our biomarkers that actually have really strong value and utilize them in a manner that is pragmatic. It can actually introduce and take full advantage of them, and so I think this is a great opportunity for us to rethink our usual approach, which frankly, especially for troponin has really been very binary and very static. Thank you so much Dr Mills for the innovation and the willingness to look into this area. Dr. Carolyn Lam: Thank you so much. This paper is like a sneak peak into the future of what we'll be practicing medicine like. Well, audience, you heard it right here on Circulation on the Run. Don't forget to tune in again next week. This program is copyright American Heart Association 2019.

Prime Minister Lee Hsien Loong held his annual National Day Rally. Glenn van Zutphen speaks to Jeff Ng, Head of Continuum Economics and Abhijit Visaria, Research Fellow at the Centre for Ageing Research and Education, Duke-NUS Medical School who discuss the topics that were covered during the rally including global trade relations, retirement, education and climate change.

Health Check Ep 10: Can schools and parents help boost the cognition and well-being of sleep-deprived Singaporean teenagers?  9:30 mins Synopsis: In this fortnightly podcast series on Wednesdays, The Straits Times guides you to healthier living and debunks the myths with expert guests. To discuss why teenagers and students need to sleep more and how insufficient sleep affects them, ST correspondent Joyce Teo and podcasting head Ernest Luis host Prof Michael Chee, the director of the Centre for Cognitive Neuroscience at the Duke-NUS Medical School who is a prominent sleep expert.  He answers the following questions: What can be done to help teenagers - inundated with homework, curricular activities, enrichment classes and tuition after school - sleep more? Most Singaporean adolescents sleep an average of 6.5 hours a night on the weekdays. What is a good amount of nocturnal sleep for teenagers? Is seven to eight hours a good achievable target for upper secondary school teenagers? Could shorter sleep increase the risk of diabetes among young Singaporeans? How can students manage better sleep strategy during intense examination periods?  Produced by: Joyce Teo and Ernest Luis Edited by: Adam Azlee Follow more Health Check podcasts and rate us on: Spotify: http://str.sg/oeGY  Apple Podcasts: http://str.sg/oeXP  Google Podcasts: http://str.sg/oeLN  Playlist: https://str.sg/Jw7R  Website: http://str.sg/stpodcasts  Feedback to: podcast@sph.com.sg 

Health Check Ep 10: Can schools and parents help boost the cognition and well-being of sleep-deprived Singaporean teenagers?  9:30 mins Synopsis: In this fortnightly podcast series on Wednesdays, The Straits Times guides you to healthier living and debunks the myths with expert guests. To discuss why teenagers and students need to sleep more and how insufficient sleep affects them, ST correspondent Joyce Teo and podcasting head Ernest Luis host Prof Michael Chee, the director of the Centre for Cognitive Neuroscience at the Duke-NUS Medical School who is a prominent sleep expert.  He answers the following questions: What can be done to help teenagers - inundated with homework, curricular activities, enrichment classes and tuition after school - sleep more? Most Singaporean adolescents sleep an average of 6.5 hours a night on the weekdays. What is a good amount of nocturnal sleep for teenagers? Is seven to eight hours a good achievable target for upper secondary school teenagers? Could shorter sleep increase the risk of diabetes among young Singaporeans? How can students manage better sleep strategy during intense examination periods?  Produced by: Joyce Teo and Ernest Luis Edited by: Adam Azlee Follow more Health Check podcasts and rate us on: Spotify: http://str.sg/oeGY  Apple Podcasts: http://str.sg/oeXP  Google Podcasts: http://str.sg/oeLN  Playlist: https://str.sg/Jw7R  Website: http://str.sg/stpodcasts  Feedback to: podcast@sph.com.sg  See omnystudio.com/listener for privacy information.

Health Check Ep 9: Why sleep habits need to be formed when young 9:30 mins Synopsis: In this fortnightly podcast series on Wednesdays, The Straits Times guides you to healthier living and debunks the myths with expert guests. ST correspondent Joyce Teo and podcasting head Ernest Luis host Prof Michael Chee, the director of the Centre for Cognitive Neuroscience at the Duke-NUS Medical School, a prominent sleep expert who wants to change how we think about sleep. He was asked the following questions: 1. Are we sleeping more than our neighbours in the region? What’s the evidence? 2. We all know we should prioritise sleep but many of us don't get a full night's sleep. Can we make up for the lack of sleep on weekends, or by taking afternoon naps? 3. Why do we need to have sufficient sleep? 4. What causes insomnia and is it normal for the elderly to have poor sleep? 5. Should offices have sleep pods? Produced by: Joyce Teo and Ernest Luis Edited by: Adam Azlee Follow more Health Check podcasts and rate us on: Spotify: http://str.sg/oeGY  Apple Podcasts: http://str.sg/oeXP  Google Podcasts: http://str.sg/oeLN  Playlist: https://str.sg/Jw7R  Website: http://str.sg/stpodcasts  Feedback to: podcast@sph.com.sg 

Health Check Ep 9: Why sleep habits need to be formed when young 9:30 mins Synopsis: In this fortnightly podcast series on Wednesdays, The Straits Times guides you to healthier living and debunks the myths with expert guests. ST correspondent Joyce Teo and podcasting head Ernest Luis host Prof Michael Chee, the director of the Centre for Cognitive Neuroscience at the Duke-NUS Medical School, a prominent sleep expert who wants to change how we think about sleep. He was asked the following questions: 1. Are we sleeping more than our neighbours in the region? What's the evidence? 2. We all know we should prioritise sleep but many of us don't get a full night's sleep. Can we make up for the lack of sleep on weekends, or by taking afternoon naps? 3. Why do we need to have sufficient sleep? 4. What causes insomnia and is it normal for the elderly to have poor sleep? 5. Should offices have sleep pods? Produced by: Joyce Teo and Ernest Luis Edited by: Adam Azlee Follow more Health Check podcasts and rate us on: Spotify: http://str.sg/oeGY  Apple Podcasts: http://str.sg/oeXP  Google Podcasts: http://str.sg/oeLN  Playlist: https://str.sg/Jw7R  Website: http://str.sg/stpodcasts  Feedback to: podcast@sph.com.sg  See omnystudio.com/listener for privacy information.

In this episode, we look at the potential benefits of living longer if we are happier people.  This is based on a study done by Choy-Lye Chei, June May-Ling Lee, Stefan Ma, & Rahul Malhotra at the Duke-NUS Medical School entitled "Happy Older People Live Longer" reported in the Age and Ageing, 2018.   To learn more about the Happiness Podcast, go to: http://www.HappinessPodcast.org. To learn more about Dr. Puff's Corporate Workshops, go to: http://www.SuccessBeyondYourImagination.com 

Train with 3T Fitness @www.jvimpacts.com Follow Coach JV on IG @3tfitness Follow Warrior JV on IG @jvimpacts Research has been proving the positive effects of happiness on wellness are real, which can especially be seen in a recent study from Duke-NUS Medical School in Singapore that found happy older people live longer. This study looked at 4,478 participants ages 60 and older throughout the country, over the course of six years. The findings suggest that even small amounts of incremental happiness can benefit longevity:  Every increase of one point on the happiness score lowered the chance of dying due to any cause among participants by an additional nine percent. The likelihood of dying due to any cause was 19 percent lower for happy older people. Further, the inverse association of happiness with mortality was consistently present among men and women, and among the young-old (aged 60-79 years) and the old-old (aged 75 years or older).   I don’t think this comes as shock but how many people are happy and really truly happy and why do think this is? Lets look at some factors that may be causing lack of happiness and how to create some happiness in your life. Listen Now! https://www.sciencedaily.com/releases/2018/08/180827100426.htm?utm_source=Broken+Brain&utm_campaign=e84b325256-EMAIL_CAMPAIGN_2018_03_29_COPY_01&utm_medium=email&utm_term=0_e9a7b3b4f1-e84b325256-116509341&mc_cid=e84b325256&mc_eid=bea5d4a6d4 Learn more about your ad choices. Visit megaphone.fm/adchoices

Eng Eong Ooi is Professor and Deputy Director of the Emerging Diseases Programme at Duke-NUS Medical School in Singapore. We talk about dengue fever, Singapore, and family. For more information: Eng Eong Ooi's 2011 Open Conversations Interview at Duke-NUS Eng Eong Ooi's 2013 Interview with the Cognitive Neuroscience Lab at Duke-NUS Eng Eong Ooi's 2014 Interview with AsiaNews